Demyelinating disease and vaccination of the human papillomavirus;Trastornos neurológicos desmielinizantes y vacunación del papilomavirus humano

Revista de Neurologia

Volumn 52, Issue 8, 2011, Pages 472-476

  Josefa Alvarez Soria M ^a   Hernández González, Amalia ^a   de León, Sira Carrasco García ^a   Angeles del Real Francia M ^a   Jose Gallardo Alcaniz M ^a   López Gómez, José L ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Adverse effects; Autoimmune disease; Demyelinating disease; Immunological mechanism; Molecular mimicry; Papillomavirus vaccine

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUTOIMMUNE DISEASE; CANCER PREVENTION; CASE REPORT; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MOTOR NEURON DISEASE; MYELITIS; PAPILLOMAVIRUS INFECTION; SEIZURE; VACCINATION;

EID: 79955685538     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5208.2010243     Document Type: Article

References (26)

1. Bosch FX, De Sanjosé S. Chapter 1: human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
2. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007; 369: 1861-1868.
3. Garland S, Hernández-Ávila M, Wheeler CM, Pérez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
5. Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescent and young adult women. Pediatrics 2006; 118: 2135-2145.
6. Slade A, Leidel L, Vellozzi C, Woo E, Hua W, Sutherland A, et al. Poslicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-757.
7. Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 2008; 26: 4417-4419.
8. Montalbán X, Tintoré M, Swanton J, Barkhof F, Fazekas F, Filippi M, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74: 427-434.
9. Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, et al. Acute disseminated encephalomyelitis. Arch Neurol 2005; 65: 1673-1680.
10. Erazo-Torricelli R. Encefalomielitis aguda diseminada en la niñez. Rev Neurol 2006; 42 (Supl 3): S75-82.
11. Iñíguez C, Mauri JA, Larrodé J, López del Val J. Jericó I, Morales F. Mielitis transversa aguda secundaria a la vacunación de la hepatitis B. Rev Neurol 2000; 31: 430-432.
12. Peña JA, Montiel-Nava C, Hernández F, Medrano E, Valbuena O, Cardozo J. Encefalomielitis aguda diseminada en niños. Rev Neurol 2002; 34: 163-168.
13. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology 2009; 16: 2132-2133.
14. Garg RK. Acute disseminated encephalomyelitis. Postgrad Med J 2003; 79: 11-17.
15. Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008; 15: 1315-1322.
16. Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009; 15: 116-119.
17. Bomprezzi R. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2010; 74: 864-865.
18. Mendoza P, González L, Fernández S, Muñiz M. Encefalomielitis aguda diseminada con lesiones tumefactas tras vacunación contra el virus del papiloma humano. Neurologia 2010; 25: 58-59.
19. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, et al. Adverse events reported following live, cold adapted, intranasal influenza vaccine. JAMA 2005; 294: 2720-2725.
20. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006; 55: 1120-1124.
21. Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barré syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 1981; 9 (Suppl): S31-S38.
22. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979; 110: 105-123.
23. Miravalle A, Ross K. Encephalitis complicating smallpox vaccination. Arch Neurol 2003; 60: 925-928.
24. Lassmann H. Acute disseminated encephalomyelitis and multiple sclerosis. Brain 2010; 133: 317-319.
25. Destefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-509.
26. López-Pisón J, García-Bodega O, Díaz-Suárez M, Bajo-Delgado AF, Cabrerizo de Diago R, Peña-Segura JL. Inflamación diseminada episódica del sistema nervioso central en niños. Revisión casuística de un período de 13 años. Rev Neurol 2004; 38: 405-410.